ArticleInternal medicine journal2025
Association between serum uric acid levels and galectin-3 in patients with uncomplicated type 2 diabetes.
Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Galectin-3 and Presepsin Levels in Pediatric Familial Mediterranean Fever Patients During Remission: A Prospective Study.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum uric acid (SUA) has been associated with an increased risk of cardiovascular disease (CVD) in both the general population and individuals with type 2 diabetes (T2DM). Identification of high-risk individuals is crucial for the primary prevention of CVD. A growing array of newly discovered biomarkers has been identified for predicting CVD. Galectin-3 (Gal-3) is linked to inflammatory and fibrotic processes and has been suggested as a biomarker in patients with heart failure.
aimsOur aim is to investigate whether Gal-3 is a marker that may predict the risk of CVD caused by asymptomatic hyperuricemia in patients with uncomplicated T2DM.
methodsTwenty patients (male/female: 10/10) with T2DM with high SUA levels and 20 controls (male/female: 10/10) matched for age and gender with T2DM with normal SUA levels were involved.
resultsSUA and Gal-3 levels exhibited a statistically significant correlation (r
conclusionsThe present study is the first to show a correlation between the level of SUA and Gal-3 in patients with uncomplicated T2DM. This result suggests that Gal-3 could potentially serve as a marker to predict the risk of CVD in patients with uncomplicated T2DM with high SUA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.